Form 4: Jazz Pharmaceuticals Executive Samantha Pearce Reports Share Transactions Following Vesting of Performance Awards

Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, Samantha Pearce, reports acquisition of shares through performance award vesting and a stock purchase plan, along with a disposition of shares to cover tax obligations.

Summary

• Samantha Pearce, EVP and Chief Commercial Officer at Jazz Pharmaceuticals, reported several transactions involving ordinary shares.
• On January 17, 2025, 2,533 ordinary shares were acquired due to the vesting of performance share awards granted on March 3, 2022.
• The performance-based vesting requirements were met on January 17, 2025.
• Additionally, 166 ordinary shares were acquired on November 29, 2024, through an Employee Stock Purchase Plan.
• To cover tax obligations, 1,365 shares were disposed of at a price of $122.62 per share on January 17, 2025.
• Following these transactions, Ms. Pearce beneficially owns 25,412 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive share transactions, which are generally neutral to positive. The vesting of performance awards suggests that performance goals were met, which is a positive sign. The sale of shares for tax obligations is a normal occurrence and does not indicate a negative sentiment.

Positives

• The vesting of performance awards indicates that performance goals were achieved.
• The acquisition of shares through the Employee Stock Purchase Plan shows confidence in the company's future.

Negatives

• The disposal of 1,365 shares to cover tax obligations reduces the total number of shares held by Ms. Pearce.

Risks

• The sale of shares to cover tax obligations could be perceived negatively by some investors, although it is a common practice.
• Fluctuations in the stock price could impact the value of the shares held by Ms. Pearce.

Industry Context

This is a routine disclosure of share transactions by a company executive, which is common in the pharmaceutical industry. It reflects the standard practice of equity-based compensation and tax obligations.

Comparison to Industry Standards

• Share transactions by executives are a common occurrence in publicly traded companies, particularly in the pharmaceutical sector.
• Companies like Gilead Sciences, Amgen, and Biogen also regularly report similar transactions by their executives.
• The vesting of performance-based awards is a standard practice to align executive compensation with company performance.
• The use of employee stock purchase plans is also a common benefit offered by many companies to their employees.

Stakeholder Impact

• Shareholders may view the vesting of performance awards as a positive sign of company performance.
• Employees may be encouraged by the availability of the Employee Stock Purchase Plan.
• The transactions have a minimal impact on other stakeholders.

Key Dates

Keywords

Jazz Pharmaceuticals, Samantha Pearce, share transactions, performance awards, stock purchase plan, insider trading, executive compensation, vesting, tax obligations